symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
MDGL,140.52,-0.728655,387218,2770956036,0,57.21-322.67,-0.5,"Madrigal Pharmaceuticals, Inc.",USD,0001157601,US5588681057,558868105,NASDAQ Global Select,NASDAQ,Biotechnology,https://www.madrigalpharma.com,"Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ÃŸ agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.",Mr. William J. Sibold,Healthcare,US,92,267 824 2827,Four Tower Bridge,West Conshohocken,PA,19428,220.727,68.7734,https://financialmodelingprep.com/image-stock/MDGL.png,2007-02-06,False,False,True,False,False
